Accéder au contenu
Merck

Lithium augmentation in venlafaxine non-responders: an open study.

European psychiatry : the journal of the Association of European Psychiatrists (2003-11-13)
G Bertschy, E Ragama-Pardos, A Aït-Ameur, M Muscionico, S Favre, L Roth
RÉSUMÉ

Thirteen major depressive patients not responding to a 4-week venlafaxine 300 mg treatment were eligible for a 4-week open trial of lithium addition. Two patients had to stop lithium for a possible moderate serotonin syndrome and five patients became responders, including one dramatic response and two semi-rapid responses.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Sulfate de lithium, ≥98.5% (titration)
Sigma-Aldrich
Sulfate de lithium, ≥99.99% trace metals basis
Sigma-Aldrich
Sulfate de lithium, purum p.a., ≥98.0% (T)